Multiple outlets report that Ceretas is named the “ASX Runner of the Week,” following its debut on the Australian Securities Exchange. The company is described as developing portable, therapeutic ultrasound technology aimed at treating Alzheimer’s disease and dementia. The coverage presents Ceretas as the featured company across the “Bulls N’ Bears ASX Runner of the Week” segment, with the emphasis on its technology’s intended medical applications. In addition to Ceretas, the segment title references other companies, including Pacgold and Hamelin Gold, but the provided summaries focus specifically on Ceretas and its early-stage activity tied to its ultrasound approach. The reports do not provide further details in the shared text on clinical trial status, partnerships, financial performance, or timelines. Overall, the common theme is that Ceretas’ ASX listing coincides with investor attention on its portable therapeutic ultrasound platform and its targeted focus on neurodegenerative conditions such as Alzheimer’s disease and dementia.